Vidarbha News

DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Advanced Gastric Carcinoma Clinical Trial Pipeline Landscape

 Breaking News
  • No posts were found

DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Advanced Gastric Carcinoma Clinical Trial Pipeline Landscape

September 05
23:16 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Advanced Gastric Carcinoma Clinical Trial Pipeline Landscape

The Advanced Gastric Carcinoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Gastric Carcinoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Gastric Carcinoma pipeline landscape and fostering the potential growth of Advanced Gastric Carcinoma therapeutic advancements.

 

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

  • DelveInsight’s Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
  • The leading companies working in the Advanced Gastric Carcinoma market include Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co. Ltd, Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
  • Promising Advanced Gastric Carcinoma Pipeline Therapies in the various stages of development include Mitoxantrone Hydrochloride Liposome, intravenous injection, pemetrexed, oxaliplatin, Catumaxomab, Cisplatin, Everolimus, MRG003, AUY922, Docetaxel, Irinotecan, Pamiparib, Apatinib, HM781-36B(Poziotinib), Trastuzumab, LJM716, Trastuzumab, and others.
  • On January 2023, Linton Pharma Co. Ltd announced a study of Phase 3 clinical trials for Catumaxomab. Subjects at the first and second stages will continue the treatment until one of the following conditions occurs: 1) Significant progression of tumor lesions, including but not limited to peritoneal metastases lesions and/or ascites; 2)Intolerable toxicity; 3)The investigator believes that patients need to withdraw from the study and receive other treatment;4)death;5)Withdrawal of informed consent.
  • On January 2023 BeiGene announced a study of Phase 2 clinical trials for Pamiparib. This study will enroll participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants will receive BGB-290; in Arm B participants will receive placebo. The purpose of this study is to show that BGB-290 (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
  • On April 2023, Do-Youn Oh, Seoul National University Hospital announced a study of Phase 2 clinical trials for Paclitaxel, Olaparib, and Durvalumab. The dynamics of immune systems by Olaparib and its changes by combination with immune-oncology agents will be uncovered. The combination of Olaparib with Durvalumab with paclitaxel is tolerable and efficacious in gastric cancer.
  • On June 2023, Bristol-Myers Squibb announced a study of Phase 2 clinical trials for Nivolumab, Ipilimumab, Relatlimab, BMS-986205, and Rucaparib. The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

 

Request a sample and discover the recent advances in Advanced Gastric Carcinoma Treatment Drugs @ Advanced Gastric Carcinoma Infection Pipeline Report

 

The Advanced Gastric Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Gastric Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Gastric Carcinoma clinical trial landscape.

 

Advanced Gastric Carcinoma Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum).

 

Find out more about Advanced Gastric Carcinoma Treatment Drugs @ Drugs for Advanced Gastric Carcinoma Treatment

 

Advanced Gastric Carcinoma Emerging Drugs Profile

  • Camrelizumab: Jiangsu Hengrui Medicine
  • Pamiparib: BeiGene

 

Advanced Gastric Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The Advanced Gastric Carcinoma companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

 

Learn more about the emerging Advanced Gastric Carcinoma Pipeline Therapies @ Advanced Gastric Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Gastric Carcinoma Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Gastric Carcinoma Companies- Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co. Ltd, Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
  • Advanced Gastric Carcinoma Pipeline Therapies- Mitoxantrone Hydrochloride Liposome, intravenous injection, pemetrexed, oxaliplatin, Catumaxomab, Cisplatin, Everolimus, MRG003, AUY922, Docetaxel, Irinotecan, Pamiparib, Apatinib, HM781-36B(Poziotinib), Trastuzumab, LJM716, Trastuzumab, and others.

 

Dive deep into rich insights for new drugs for Advanced Gastric Carcinoma treatment, Visit @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Gastric Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Camrelizumab: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pamiparib: BeiGene
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Venadaparib: Idience
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Gastric Carcinoma Key Companies
  21. Advanced Gastric Carcinoma Key Products
  22. Advanced Gastric Carcinoma- Unmet Needs
  23. Advanced Gastric Carcinoma- Market Drivers and Barriers
  24. Advanced Gastric Carcinoma- Future Perspectives and Conclusion
  25. Advanced Gastric Carcinoma Analyst Views
  26. Advanced Gastric Carcinoma Key Companies
  27. Appendix

 

For further information on the Advanced Gastric Carcinoma pipeline therapeutics, reach out to Advanced Gastric Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Categories